Technology Platforms

We strategically focus on the development of antibodies that stimulate the immune system to deplete target pathogenic cells, including three mechanisms: redirecting NK cells to kill target cells, redirecting T cells to kill target cells and infusing multi-specific antibody with immune stimulation activity. For this purpose, we have built proprietary antibody technology platforms, encompassing the process from antibody discovery to development. This enable us to design, evaluate, select and develop optimal drug candidates in an efficient and effective manner.
ADCC-enhanced Antibody Platform
Enhance NK-cell function through antibody glycosylation modification
Multi-specific Antibody Platform
Biology function-driven and structurally design
Antibody Discovery and Optimization Platform
Screen for candidates with high efficiency and low toxicity

Technology Platforms Manufacturing

Home / R&D and Science / Technology Platforms

ADCC-enhanced Antibody Platform

Our ADCC-enhanced antibody platform is one of the leading platforms in the world to enhance NK-cell function through antibody glycosylation modification. It also meets GMP manufacturing standards in China and has undergone clinical validation.We developed various marketed or clinical‑stage antibody drugs using this platform, including Bejescin® (Obinutuzumab Beta Injection) etc.

Multi-specific Antibody Platform

The distinctive features of our multi-specific antibody platform are biology function driven and structurally designed with enhanced flexibility and efficiency. The platform enables us to construct multi-specific antibodies quickly which facilitates the efficient production of multi-specific antibodies. Our multi-specific antibody platform enables us to develop antibodies simultaneously binding to different targets to achieve synergistic therapeutic functions. The major types of multi-specific antibody structure we are developing are set forth as below.

Half-Life Extended Antibody Platform

Our Half-Life Extended Antibody Platform integrates advanced antibody engineering technologies, aiming to optimize the pharmacokinetic properties of antibody drugs, extend antibody half-life, reduce clearance rate, and decrease dosing frequency, thereby improving patient compliance in disease treatment. We have developed a series of antibody drugs using this platform, including MIL116 and other candidates.

Antibody Discovery and Optimization Platform

We have developed a proprietary antibody discovery and optimization platform that screens for antibodies with enhanced binding affinity and stability, constructs antibodies specifically activated in the tumor environment, and design multi-specific antibodies with enhanced scFv stability.